

Longevity Indices - Is the time ripe?


Mortality & Longevity Seminar 2018

Steven Baxter Hymans Robertson LLP

steven.baxter@hymans.co.uk

Index vs indemnity longevity swaps

A quick reminder





Index vs indemnity longevity swaps

Risk protection

Data Risk



Event Risk



Basis Risk

"update projections for one year of new population data"

"update projections as cure for cancer discovered" "scheme/portfolio will not mirror population trends"

Indemnity







Index











Historical reflections



Transactions to date



LifeMetrics index-based swap

2012

- 10 year duration
 - Non-pensioners

Delta Lloyd

- Dutch pensions and annuity policyholders
- Two transactions with RGA

2015

• Duration of 6 years (2014) and 8 years (2015)

2016

Each covering c. €12bn longevity reserves (c. €350m notional)

2008 2009 2010 2011

Lucida

LifeMetrics index-based swap

- "q-forward"
- First use by insurance company

Aegon

2013

- Dutch annuitants
- Three transactions with various counterparties inc. SCOR and Deutsche Bank

2014

• Covering a total of c. €20bn longevity reserves

NN

2018

- Dutch pension fund and annuitant policyholders
- Single transaction with Hannover Re
- Covering c. €3bn longevity reserves

Pension schemes

Insurance companies



Why the (UK) hiatus?

Theoretically...

Price Index swap < Price Indemnity swap

- Materially simpler to administer
 - e.g. no need for multiple parties to track members
- Less 'portfolio-specific' analysis
- Standardised contracts
- Lower barrier to entry => more competition



Reality?...


Price Index swap > Price Indemnity swap


Price Index swap *not suff* < Price Indemnity swap

- Supply: Additional sources of capital (e.g. capital markets) have <u>higher</u> return on capital requirement?
- Supply: Preference for indemnity? Not passing on administration savings in pricing?
- Demand: Risk-reward dynamic saving from index not sufficient to compensate for retaining some risk



Writing longevity for "better than free"







- If an insurer writes one risk only then ever additional unit of business costs the same in overall (total) capital (1)
- Adding a new, different risk introduces diversification and is capital efficient (less capital per unit of extra business) (2)



Writing longevity for "better than free"





- For a **negatively correlated risk** it is possible capital reduces e.g. reinsurers with lots of mortality risk (life insurance) pricing for longevity
- Will reach an **optimal** mix of business between risks (4)
 - Reinsurer constrained to maintaining this mix
 - New entrants (light on longevity, heavy on mortality) are able to offer better prices (all else being equal)



Why indemnity not index?

To date...

- Cedant demand ('get me out of here...')
- <u>Lack</u> of confidence in index
- Plenty of cheap (mortality) capital to support indemnity
- Suppliers have systems for, or were willing to create systems, for managing indemnity

Looking forward

- Cedant demand changing (deferreds, 'trickier' indemnity cases, tail risk protection...)
- <u>Growing</u> body of work showing hedge effectiveness
- <u>Reducing</u> (mortality) capital to support indemnity
- Can existing systems cope with changing demands e.g. deferred pensioners?
- New entrants less willing to invest in indemnity systems / upskilling?

19 June 2018

Institute and Faculty of Actuaries





What will it take for the UK index market to take off?



The longevity "ecosystem"

Now

Capital Markets

Reinsurers



Insurers



Pension Schemes



Beneficiaries



Global mortality risk market can potentially support 'diversification benefit' for c. 100% of UK longevity risk (currently)

Source: Own high-level and preliminary calculations based on estimated size of global mortality risk protection market and typical capital holdings against mortality risk per £ of sum assured. SCR only, no allowance for risk margin. No allowance for growth in global life market. Assumes global applicability of SII, standard formula level stresses for mortality risk and 'typical' internal model stresses for longevity.



c.£2trn+ of private sector pension liabilities exposed to longevity risk

Source: Still Living with Mortality: The longevity risk Transfer Market after One Decade, Blake et al



Indemnity




Fee + fixed leg



The longevity "ecosystem"

Future?

Cost effective (broad) protection where insurance regime has high capital requirements (so cost of capital) e.g. tail risks, deferreds, ...





Achieving index cheaper than indemnity

Price Indemnity ↑

Demand

- Smaller schemes
- Deferred pensioners
- 'Difficult' cases

Supply

- Less capital available
- Less mortality diversification benefit

Price Index \

 Increased confidence in level of risk protection

- Regulatory enthusiasm
- New (broader) entrants
- Attractive to capital markets



13




Overcoming the final hurdles...


- Value for money risk reduction
- Term matters attraction to capital markets
- Regulatory appetite

Value for money: Basis risk

Population Index



Portfolio



Basis Risk

- Population indices equally weight each person
- Specific portfolios have
 - Greater exposure to binomial risk
 - Different socio-economic mix to population
 - Unequal mix of <u>liability</u> exposure
- Portfolio experience <u>will</u> differ from the index
- How much less than 100% 'hedge'?



2010-2015: A case in point






Source: Club Vita & PLSA 'Longevity Trends: One Size Fits All'

Note that Comfortable / Making Do / Hard-Pressed evenly split on lives basis. Average 5 year improvement on a liability weighted basis c. 1.7%.




of Actuaries

Value for money: How much basis risk?



Value for money: Narrowing the gap



Club Vita
Forthcoming, Longevity 14


2018

80% - 90%?

- Portfolio level
- Variety of metrics
- * Very early indications of potential results range for large portfolios.
 Subject to detailed review and stress testing of modelling.



Value for money: One year VaR / Solvency II



Technical notes:

Indicative relative sizes of event and data based upon analysis of PRA Quantitative Indicators in "Making the most of an Internal Model" presented to Risks in Life, 2 February 2017. Firms individual internal models will give different weights to these risks, may include other risks, and may have a different definition of event risk. Inclusion of Basis Risk is an addition to the PRA QIs. Aggregate risk level assumes an independence of risk for simplicity. This may differ from Firms' internal models and from PRA application of QIs.




Attractive to Capital Markets: Term matters


Risk Cap Markets Cedant Short Long 2-5 yrs 30+ yrs Removal of risk Credit Crunch Indemnity Basel III benchmark "Anti-exoticism"



20

Attractive to Capital Markets: Meeting in the 'middle'?





- Formulaic
- Assesses 'anticipated' deviation post time
 T, based on experience up to time T
- Take PV to get a settlement "bullet" payment at time T

Source of additional 'basis risk'



Regulatory Enthusiasm / Challenges



22



Summing up



Longevity indices – is the time ripe?

- 2 Do you think we will we ever see a (material) UK longevity index market?
- Will it be based on population indices or something more granular?
- ? How long will it take for the first 3 index deals in the UK?



Questions

Comments

The views expressed in this presentation are those of invited contributors and not necessarily those of the IFoA. The IFoA do not endorse any of the views stated, nor any claims or representations made in this presentation and accept no responsibility or liability to any person for loss or damage suffered as a consequence of their placing reliance upon any view, claim or representation made in this presentation.

The information and expressions of opinion contained in this publication are not intended to be a comprehensive study, nor to provide actuarial advice or advice of any nature and should not be treated as a substitute for specific advice concerning individual situations. On no account may any part of this presentation be reproduced without the written permission of the IFoA or Hymans Robertson LLP.

